<cite id="njbft"></cite><var id="njbft"><video id="njbft"></video></var>
<var id="njbft"></var>
<listing id="njbft"></listing>
<cite id="njbft"></cite>
<menuitem id="njbft"><strike id="njbft"></strike></menuitem><var id="njbft"></var> <var id="njbft"><strike id="njbft"><thead id="njbft"></thead></strike></var><var id="njbft"><video id="njbft"></video></var>
<cite id="njbft"><video id="njbft"><menuitem id="njbft"></menuitem></video></cite>
新闻资讯
科思
/
/
/
Bioresorbable vascular scaffold implantation in acute coronary syndromes: clinical evidence, tips and tricks

Bioresorbable vascular scaffold implantation in acute coronary syndromes: clinical evidence, tips and tricks

  • 分类:学术论文
  • 作者:
  • 来源:
  • 发布时间:2016-08-12 09:23
  • 访问量:

【概要描述】 Percutaneous coronary intervention (PCI) with a drug-eluting stent (DES) is routine treatment for patients with acute coronary syndromes (ACS). However, permanent metallic caging of the vessel has several shortcomings, such as side branch jailing and impossibility of late lumen enlargement.

Bioresorbable vascular scaffold implantation in acute coronary syndromes: clinical evidence, tips and tricks

【概要描述】 Percutaneous coronary intervention (PCI) with a drug-eluting stent (DES) is routine treatment for patients with acute coronary syndromes (ACS). However, permanent metallic caging of the vessel has several shortcomings, such as side branch jailing and impossibility of late lumen enlargement.

  • 分类:学术论文
  • 作者:
  • 来源:
  • 发布时间:2016-08-12 09:23
  • 访问量:
详情

  Percutaneous coronary intervention (PCI) with a drug-eluting stent (DES) is routine treatment for patients with acute coronary syndromes (ACS). However, permanent metallic caging of the vessel has several shortcomings, such as side branch jailing and impossibility of late lumen enlargement. Moreover, DES PCI is affected by vasomotion impairment. In ACS a high thrombus burden and vasospasm lead to a higher risk of acute and late acquired stent malapposition than in stable patients. This increases the risk of acute, late and very late stent thrombosis. In this challenging clinical setting, the implantation of bioresorbable vascular scaffolds (BVS) could represent an appealing therapeutic option. Temporary vessel scaffolding has proved to have several advantages over metallic stent delivery, such as framework reabsorption, late lumen enlargement, side branch patency, and recovery of physiological reactivity to vasoactive stimuli. In the thrombotic environment of ACS, BVS implantation has the benefit of capping the thrombus and the vulnerable plaque. Bioresorbable vascular scaffolds also seems to reduce the incidence of angina during follow-up. Acute coronary syndromes patients may therefore benefit more from temporary polymeric caging than from permanent stent platform implantation. The aim of this review is to update the available knowledge concerning the use of BVS in ACS patients, by analyzing the potential pitfalls in this challenging clinical setting and presenting tricks to overcome these limitations.

阿迈特“易泊EZPo?”支架定位系统在河南省胸科医院成功完成上市后临床应用
2023 08-12

阿迈特“易泊EZPo?”支架定位系统在河南省胸科医院成功完成上市后临床应用

北京阿迈特的颅内球囊扩张导管产品获批上市
2023 08-10

北京阿迈特的颅内球囊扩张导管产品获批上市

喜报—北京阿迈特医疗器械有限公司取得国医械华光认证GB/T 42061-2022 idt ISO13485:2016医疗器械质量管理体系认证证书
2023 07-21

喜报—北京阿迈特医疗器械有限公司取得国医械华光认证GB/T 42061-2022 idt ISO13485:2016医疗器械质量管理体系认证证书

公司信息

北京阿迈特医疗器械有限公司

Beijing Advanced Medical Technologies,Ltd.Inc.

联系我们

地址:北京市大兴区永旺西路26号院中关村医疗器械园11号楼

电话:010-6297-7955             邮箱:amt@ametcorp.com

联系我们

地址:北京市大兴区永旺西路26号院中关村医疗器械园11号楼

电话:010-6297-7955             

邮箱:amt@ametcorp.com

久久99精品国产自在现线小黄鸭,亚洲国产精品一区二区玖玖爱,亚洲日韩精品无码av海量国产精,日产精品久久久1区2区_影院 久久久久久久久亚洲精品_久久久一区二区人妻av_国产午夜影院黄色片_日韩一区二区在线视频 精品久久久久久久中文字幕|十八禁无码免费网站|A片免费一级无码|人妻被按摩到潮喷中文字幕 色欲天天_久久精彩_精品日本一区二区三区在线观看_精品久久久久无码人妻中文字幕 欧美性战a久久久久久_91精品无码一区_欧美oumeisetu_久久国产乱子伦精 久久久午夜视频,久久国产第一区二区三区日韩精品,欧美综合精品激情久久久久,国内精品一区二区